Third Rock Ventures
-
StartUPDATES: New developments for healthcare startups
Check out news from Opala, Equiva, Sling Therapeutics, Quil, and Third Rock Ventures.
-
Biotech startup Septerna lands $100M to break new ground on an old drug target
Septerna has science from a Nobel laureate and technology that finds new ways to drug GPCRs, well-validated receptors targeted by about one-third of FDA-approved medicines. According to CEO Jeff Finer, the startup is kicking off a second golden age of GPCR drug development.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Third Rock-backed Abata gets $95M to take cell therapy to MS, other autoimmune diseases
Regulatory T cells, or Tregs, have shown promise as a treatment for autoimmune diseases. Abata Therapeutics has raised $95 million in Series A financing for its Treg technology and CEO Samantha Singer said that multiple sclerosis is the startup’s first disease target.
-
Liquid biopsy firm Thrive launches with $110M Series A round
The company has a 10,000-patient prospective trial with Geisinger fully enrolled to test CancerSEEK, a test developed at Johns Hopkins University.
-
Maze Therapeutics launches with nearly $200M to explore genetic modifiers’ role in disease
Third Rock and ARCH led the launch of the company, which will look at ways to target genetic modifiers that can protect against certain diseases.
-
Life sciences VC investment trends similar to tech, but there are differences
Deals worth $50 million or more are becoming more frequent, even in Series A. But a VC investor said underlying drivers in life sciences are different from the technology sector.
-
Ambys Medicines garners $140 million to develop chronic liver disease treatments
The company secured $60 million in a Series A round from Third Rock and Takeda, plus a partnership with Takeda.
-
Third Rock invests $55M in ‘kidney renaissance’ startup
Third Rock Ventures has incubated, funded and launched another startup, Goldfinch Bio, committing $55M to its mission to modernize the treatment of kidney disease.
-
BioPharma, Pharma, Startups, SYN
Third Rock Ventures closes $616 million healthcare fund
Boston-based Third Rock Ventures announced Monday that it had closed its largest fund to date, raising $616 million for new investments in neurology, immunology, genetic disorders and more.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Protein-motion startup launches armed with $57M to develop drugs, crack cancer code
Relay Therapeutics is aiming to identify the way proteins in cells move and shift and morph, and this understanding can help open the door to new, more effective drugs.
-
NinePoint Medical adds roughly $31M to back its imaging technology
Massachusetts-based NinePoint Medical has raised about $30.7 million to go toward its medical imaging technology that allows visibility to large areas of tissue in order to more precisely detect areas that would need to be biopsied.
-
Devices & Diagnostics, Pharma, Startups
MIT develops implantable micro-device that gauges efficacy of cancer drugs; Third Rock partner involved
With precision medicine in its infancy, it’s still difficult to determine which chemotherapy drugs are appropriate for […]
-
Devices & Diagnostics, Diagnostics, Startups
With IP from Mass Gen & funding from Third Rock, NinePoint carves niche in in-vivo imaging
When NinePoint Medical Inc. got its first seed funding from Third Rock Ventures and Prospect […]
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
